Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration, Institute of Medical Climatology and Rehabilitative Treatment, 690105 Vladivostok, Russia.
A.V. Zhirmunsky National Scientific Center of Marine Biology (Far Eastern Branch), Russian Academy of Sciences, 17 Palchevskogo Str., 690041 Vladivostok, Russia.
Mar Drugs. 2023 Jun 7;21(6):351. doi: 10.3390/md21060351.
Asthma associated with obesity is considered the most severe phenotype and can be challenging to manage with standard medications. Marine-derived 1--alkyl-glycerols (AGs), as precursors for plasmalogen synthesis, have high biological activity, making them a promising substance for pharmacology. This study aimed to investigate the effect of AGs from squid on lung function, fatty acid and plasmalogen levels, and cytokine and adipokine production in obese patients with asthma. The investigational trial included 19 patients with mild asthma associated with obesity who received 0.4 g of AGs daily for three months in addition to their standard treatment. The effects of AGs were evaluated at one and three months of treatment. The results of the study demonstrated that intake of AGs increased the FEV1 and FEV1/VC ratios, and significantly decreased the ACQ score in 17 of the 19 patients after three months of treatment. The intake of AGs increased concentration of plasmalogen and n-3 PUFA in plasma, and modified leptin/adiponectin production by adipose tissue. The supplementation of AGs decreased the plasma levels of inflammatory cytokines (TNF-α, IL-4, and IL-17a), and oxylipins (TXB2 and LTB4), suggesting an anti-inflammatory property of AGs. In conclusion, 1--alkyl-glycerols could be a promising dietary supplement for improving pulmonary function and reducing inflammation in obese asthma patients, and a natural source for plasmalogen synthesis. The study highlighted that the beneficial effects of AG consumption can be observed after one month of treatment, with gradual improvement after three months of supplementation.
肥胖相关性哮喘被认为是最严重的表型，用标准药物治疗可能具有挑战性。海洋来源的 1-烷基甘油（AGs）作为磷脂酰基醇合成的前体，具有很高的生物活性，是一种很有前途的药理学物质。本研究旨在探讨鱿鱼来源的 AGs 对肥胖伴哮喘患者肺功能、脂肪酸和磷脂酰基醇水平以及细胞因子和脂肪因子产生的影响。该研究包括 19 名轻度哮喘合并肥胖的患者，他们在标准治疗的基础上每天额外服用 0.4 克 AGs，持续三个月。在治疗的一个月和三个月时评估 AGs 的效果。研究结果表明，19 名患者中有 17 名在三个月的治疗后，AGs 的摄入增加了 FEV1 和 FEV1/VC 比值，并显著降低了 ACQ 评分。AGs 的摄入增加了血浆中磷脂酰基醇和 n-3PUFA 的浓度，并改变了脂肪组织中瘦素/脂联素的产生。AGs 的补充降低了血浆中炎症细胞因子（TNF-α、IL-4 和 IL-17a）和氧化脂类（TXB2 和 LTB4）的水平，表明 AGs 具有抗炎作用。总之，1-烷基甘油可能是改善肥胖哮喘患者肺功能和减轻炎症的有前途的膳食补充剂，也是合成磷脂酰基醇的天然来源。该研究表明，AG 消耗的有益效果在治疗一个月后即可观察到，三个月后补充效果逐渐改善。
